(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 60.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 52.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.05%.
Soleno Therapeutics's revenue in 2026 is $285,008,000.On average, 12 Wall Street analysts forecast SLNO's revenue for 2026 to be $24,855,055,701, with the lowest SLNO revenue forecast at $22,148,456,468, and the highest SLNO revenue forecast at $28,391,928,877. On average, 11 Wall Street analysts forecast SLNO's revenue for 2027 to be $37,375,357,414, with the lowest SLNO revenue forecast at $27,551,230,906, and the highest SLNO revenue forecast at $45,149,077,339.
In 2028, SLNO is forecast to generate $52,901,949,205 in revenue, with the lowest revenue forecast at $39,585,251,647 and the highest revenue forecast at $60,719,971,255.